CD40LG and neoplasm: Finally, immunovirotherapy may confer benefit to other strategies aimed at inducing anti-tumor immune responses, such as CD40L costimulation,17 bispecific T cell engagers (BiTEs),18 incorporation of immunostimulatory genes such as interleukin-12 (IL-12),19 or checkpoint inhibitors.20